Page 15 - EASL Recommendations on Treatment of Hepatitis C 2015 - Summary
P. 15
14. Follow-up of untreated patients 15. Treatment of acute hepatitis C
and of patients with treatment failure
• Based on existing data, PegIFN-α monotherapy
• Untreated patients with chronic hepatitis C and those (PegIFN-α2a, 180 µg/week or PegIFN-α2b, 1.5 µg/kg/
who failed prior treatment should be regularly followed week) for 12 weeks can be used in patients with acute
(A1) hepatitis C, who will achieve SVR in as many as 90% of
cases (A1)
• Non-invasive methods for staging fibrosis are best
suited for follow-up assessment at intervals (A1) • PegIFN-α (PegIFN-α2a, 180 µg/week or PegIFN-α2b,
1.5 µg/kg/week) should be combined with daily weight-
• HCC surveillance must be continued indefinitely in based ribavirin (1000 or 1200 mg in patients <75 kg or
patients with cirrhosis (A1) ≥75 kg, respectively) for 24 weeks in patients with acute
hepatitis C who are HIV-coinfected (B1)
• Although no data is available yet, IFN-free regimens
can be used in these patients as they are expected to
achieve high SVR rates. The same doses and durations
as for patients with chronic hepatitis C can be used,
without ribavirin, until new data indicate whether shorter
and/or less intensive treatment is sufficient to achieve
high infection cure rates (B1)
• There is no indication for antiviral therapy as post-
exposure prophylaxis in the absence of documented
HCV transmission (B1)
16. Conflict of interest Xavier Forns
Grant and research support: Janssen. Advisory Boards:
Jean-Michel Pawlotsky Abbvie, Gilead, and Janssen. Speaking and teaching:
Grant and research support: Gilead. Advisory Boards: Gilead, and Janssen.
Abbvie, Achillion, Bristol-Myers Squibb, Gilead, Janssen, Massimo Puoti
Merck. Speaking and teaching: Abbvie, Bristol-Myers Grant and research support: Gilead. Advisory Boards:
Squibb, Gilead, Janssen, Merck, and Roche. Abbvie, Bristol-Myers Squibb, Gilead, Janssen, and
Alessio Aghemo Merck. Speaking and teaching: Bristol-Myers Squibb,
Advisory Boards: Abbvie, Gilead, Janssen, and Merck. Gilead, Janssen, and Merck.
Speaking and teaching: Abbvie, Bristol-Myers Squibb, Christoph Sarrazin
Gilead, Janssen, Merck, and Roche. Grant and research support: Abbott Molecular, Abbvie,
David Back Gilead, Janssen, Qiagen, Roche, and Siemens. Advisory
Grant and research support: Abbvie, Bristol-Myers Squibb, Boards: Abbott Molecular, Abbvie, Achillion, Bristol-Myers
Gilead, Janssen, Merck, and Viiv. Advisory Boards: Squibb, Gilead, Janssen, and Merck. Speaking and
Abbvie, Gilead, Janssen, and Merck. Speaking and teaching: Abbott Molecular, Abbvie, Bristol-Myers Squibb,
teaching: Abbvie, Bristol-Myers Squibb, Gilead, Janssen, Gilead, Janssen, Merck, Qiagen, and Siemens.
and Merck.
Geoffrey Dusheiko
Grant and research support: Abbvie, Bristol-Myers
Squibb, Gilead, GlaxoSmithKline, Janssen, and Merck.
Advisory Boards: Abbvie, Bristol-Myers Squibb, Gilead,
GlaxoSmithKline, Janssen, and Merck. Speaking
and teaching: Abbvie, Bristol-Myers Squibb, Gilead,
GlaxoSmithKline, Janssen, and Merck.
14
and of patients with treatment failure
• Based on existing data, PegIFN-α monotherapy
• Untreated patients with chronic hepatitis C and those (PegIFN-α2a, 180 µg/week or PegIFN-α2b, 1.5 µg/kg/
who failed prior treatment should be regularly followed week) for 12 weeks can be used in patients with acute
(A1) hepatitis C, who will achieve SVR in as many as 90% of
cases (A1)
• Non-invasive methods for staging fibrosis are best
suited for follow-up assessment at intervals (A1) • PegIFN-α (PegIFN-α2a, 180 µg/week or PegIFN-α2b,
1.5 µg/kg/week) should be combined with daily weight-
• HCC surveillance must be continued indefinitely in based ribavirin (1000 or 1200 mg in patients <75 kg or
patients with cirrhosis (A1) ≥75 kg, respectively) for 24 weeks in patients with acute
hepatitis C who are HIV-coinfected (B1)
• Although no data is available yet, IFN-free regimens
can be used in these patients as they are expected to
achieve high SVR rates. The same doses and durations
as for patients with chronic hepatitis C can be used,
without ribavirin, until new data indicate whether shorter
and/or less intensive treatment is sufficient to achieve
high infection cure rates (B1)
• There is no indication for antiviral therapy as post-
exposure prophylaxis in the absence of documented
HCV transmission (B1)
16. Conflict of interest Xavier Forns
Grant and research support: Janssen. Advisory Boards:
Jean-Michel Pawlotsky Abbvie, Gilead, and Janssen. Speaking and teaching:
Grant and research support: Gilead. Advisory Boards: Gilead, and Janssen.
Abbvie, Achillion, Bristol-Myers Squibb, Gilead, Janssen, Massimo Puoti
Merck. Speaking and teaching: Abbvie, Bristol-Myers Grant and research support: Gilead. Advisory Boards:
Squibb, Gilead, Janssen, Merck, and Roche. Abbvie, Bristol-Myers Squibb, Gilead, Janssen, and
Alessio Aghemo Merck. Speaking and teaching: Bristol-Myers Squibb,
Advisory Boards: Abbvie, Gilead, Janssen, and Merck. Gilead, Janssen, and Merck.
Speaking and teaching: Abbvie, Bristol-Myers Squibb, Christoph Sarrazin
Gilead, Janssen, Merck, and Roche. Grant and research support: Abbott Molecular, Abbvie,
David Back Gilead, Janssen, Qiagen, Roche, and Siemens. Advisory
Grant and research support: Abbvie, Bristol-Myers Squibb, Boards: Abbott Molecular, Abbvie, Achillion, Bristol-Myers
Gilead, Janssen, Merck, and Viiv. Advisory Boards: Squibb, Gilead, Janssen, and Merck. Speaking and
Abbvie, Gilead, Janssen, and Merck. Speaking and teaching: Abbott Molecular, Abbvie, Bristol-Myers Squibb,
teaching: Abbvie, Bristol-Myers Squibb, Gilead, Janssen, Gilead, Janssen, Merck, Qiagen, and Siemens.
and Merck.
Geoffrey Dusheiko
Grant and research support: Abbvie, Bristol-Myers
Squibb, Gilead, GlaxoSmithKline, Janssen, and Merck.
Advisory Boards: Abbvie, Bristol-Myers Squibb, Gilead,
GlaxoSmithKline, Janssen, and Merck. Speaking
and teaching: Abbvie, Bristol-Myers Squibb, Gilead,
GlaxoSmithKline, Janssen, and Merck.
14
